RGB-5088
Phase 1Biologic
RGB-5088 is one of 52 biologic programs targeting Diabete Mellitus. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
67 competitors in Type 1 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Diabeta
PfizerApproved
Cellcept
RocheApproved
Calciferol
Jazz PharmaceuticalsApproved
Opzelura
PfizerApproved
Neoral
NovartisApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Brethine
SanofiApproved
Ozempic
Novo NordiskApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 1 Diabetes Mellitus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RGB-5088. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details